Pharmacokinetics of the antiviral agent 3-deazaneplanocin A

  • R. A. Coulombe
  • R. P. Sharma
  • J. W. Huggins


The pharmacokinetics of 3-deazaneplanocin A (c3Nep), a competitive inhibitor of S-adenosyl-l-homocysteine (AdoHcy) hydrolase and novel antiviral agent, was investigated in female BALB/c mice. Animals were given a single intravenous dose of [3H]-c3Nep (0.1 mg/kg: 10 μCi), and blood and selected tissues were collected at various intervals thereafter for up to 72 h. The plasma concentration versus time data for c3Nep was best approximated by a two-compartment open model with first order elimination. The elimination half-life was 12.8 min, the area-under curve (AUC) was 3.38 μ−1. The distribution of c3Nep into tissues was not extensive. Following 30, 120 min, and 24 h after dosing, the kidneys and the liver contained the highest amount of drug, but this amount did not exceed 1 μg/g tissue. At these time periods, the majority of activity in the tissues represented labeled derivatives of c3Nep indicating that this compound was converted to stable metabolites. The presence of labeled conversion products in the blood confirmed that this drug is metabolized in vivo. The fact that c3Nep bound to plasma proteins in vitro may explain this drug’s limited tissue distribution. The half-life and tissue distribution of c3Nep were different from those of carbocyclic 3-deazaadenosine, a related adenosine nucleoside antiviral drug and AdoHcy hydrolase inhibitor.


3-Deazaneplanocin A pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Glazer R.I., Hartman K.D., Knode M.C., et al. (1986): 3-deazaneplanocin A: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun., 135, 688–694.CrossRefPubMedGoogle Scholar
  2. 2.
    Glazer R.I., Knode M.C., Tseng C.K.H., Haines D.R., Marquez V.E. (1986): 3-deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem. Pharmacol., 35, 4523–4527.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiang P.K., Richards H.H., Cantoni G.L. (1977): S-adenosyl-L-homocysteine hydrolase: analogues of S-adenosyl-L-homocysteine as potential inhibitors. Mol. Pharmacol., 13, 939–947.PubMedGoogle Scholar
  4. 4.
    De Clercq E. (1987): S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol., 36, 2657–2575.Google Scholar
  5. 5.
    Montgomery J.A., Clayton S.J., Thomas H.J., et al. (1982): Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target. J. Med. Chem., 25, 626–629.CrossRefPubMedGoogle Scholar
  6. 6.
    Cools M., De Clercq E. (1989): Correlation between the antiviral activity of acyclic and carbocyclic adenosine analogues in murine L929 cells and their inhibitory effect on L929 cell S-adenosylhomocysteine hydrolase. Biochem. Pharmacol., 38, 1061–1067.CrossRefPubMedGoogle Scholar
  7. 7.
    De Clercq E., Cools M., Balzarini J., et al. (1989): Broad-spectrum antiviral activities of neplanocin A and 3-deazaneplanocin A, and their 5′-nor derivatives. Antimicrob. Agents Chemother., 33, 1291–1297.PubMedGoogle Scholar
  8. 8.
    Oxenrider K.A., Bu G., Sitz T.O. (1993): Adenosine analogs inhibit the guanine-7-methylation of mRNA cap structures. FEBS Lett., 316, 273–277.CrossRefPubMedGoogle Scholar
  9. 9.
    Chiang P.K., Burbelo P.D., Brugh S.A., Gordon R.K., Fukuda K., Yamada Y. (1992): Activation of collagen IV gene expression of F9 teratocarcinoma cells by 3-deazaadenosine analogs. J. Biol. Chem., 267, 4988–4991.PubMedGoogle Scholar
  10. 10.
    Tseng C.K.H., Marquez V.E., Fuller F.W., et al. (1989): Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem., 32, 1442–1446.CrossRefPubMedGoogle Scholar
  11. 11.
    Coulombe Jr R.A., Huie J.M., Sharma R.P., Huggins J.W. (1993): Pharmacokinetics of the antiviral agent carbocyclic 3-deazadenosine. Drug Metab. Dispos., 21, 555–559.PubMedGoogle Scholar
  12. 12.
    El Dareer S.M., Tillery K.F., Rose L.M., Struck R.F., Hill D.L. (1990): Disposition and metabolism of carbovir in mice dosed intravenously or orally. Drug Metab. Dispos., 18, 842–845.PubMedGoogle Scholar
  13. 13.
    Ibrahim S.S., Boudinot F.D. (1991): Pharmacokinetics of 2′,3′-dideoxycytidine after high dose administration to rats. J. Pharm. Sci., 80, 36–38.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • R. A. Coulombe
    • 1
  • R. P. Sharma
    • 1
  • J. W. Huggins
    • 2
  1. 1.Programs in Toxicology and Molecular Biology, Department of Veterinary SciencesUtah State UniversityLoganUSA
  2. 2.US Army Medical Research Institute for Infectious DiseasesFort DetrickFrederickUSA

Personalised recommendations